CRVS
Corvus Pharmaceuticals Inc
11.60$
-1.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | -100.0% | – | – | – | -100.0% | – | – | – | – | – | – | |
| – | -6.7% | -17.9% | -8.7% | -4.8% | +120.0% | -50.0% | +31.8% | – | – | +11.5% | – | – | |
| – | – | -110.6% | – | – | – | -150.0% | – | – | – | – | – | – | |
| – | +0.9% | +1.9% | +1.0% | +26.9% | +14.4% | +24.8% | +5.6% | +7.4% | +17.6% | +12.4% | +42.9% | – | |
| – | +3.6% | +31.8% | -16.4% | +11.6% | +4.8% | +15.9% | -3.3% | -11.3% | +7.6% | +62.5% | -10.0% | – | |
| – | +1.6% | +10.7% | -5.1% | +22.2% | +11.7% | +22.4% | +3.4% | +3.0% | +15.3% | +22.0% | +29.7% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -10.6% | -16.8% | +37.3% | +30.4% | – | – | +21.7% | +15.5% | +239.4% | -28.8% | – | – | |
| – | – | – | – | – | – | – | -152.6% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | -152.6% | – | – | – | – | – | |
| – | – | – | – | – | – | – | -152.4% | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.